According to reports, HBM HOLDINGS-B (02142) is up more than 6%, currently gaining 6.35% to HKD 13.23, with a trading volume of HKD 9.94 million. The catalyst for this movement comes from an announcement on HBM's official WeChat account, revealing that on October 25th, the HBM-AstraZeneca Innovation Laboratory was officially inaugurated in Beijing. This marks a further deepening of the collaboration between the two companies, with the full-cycle research and development of new-generation antibody drugs entering an "accelerated channel." Together, they have established a diversified cooperative model that includes "R&D collaboration, equity investment, and the establishment of the Beijing Innovation Center," injecting new momentum into innovative drug development. In March of this year, HBM and AstraZeneca reached a global strategic partnership to co-develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions, as well as to build an innovation laboratory in Beijing to drive cutting-edge scientific research. After several months of preparation, the innovation laboratory is fully operational, and the HBM antibody drug innovation development platform and AI laboratory platform have been constructed and are set to officially launch, facilitating the development of next-generation therapeutic antibodies across various fields.